AU2002212226A1 - Use of indole derivatives for treating illnesses of the central nervous system - Google Patents

Use of indole derivatives for treating illnesses of the central nervous system

Info

Publication number
AU2002212226A1
AU2002212226A1 AU2002212226A AU1222602A AU2002212226A1 AU 2002212226 A1 AU2002212226 A1 AU 2002212226A1 AU 2002212226 A AU2002212226 A AU 2002212226A AU 1222602 A AU1222602 A AU 1222602A AU 2002212226 A1 AU2002212226 A1 AU 2002212226A1
Authority
AU
Australia
Prior art keywords
nervous system
central nervous
indole derivatives
treating illnesses
illnesses
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2002212226A
Other languages
English (en)
Inventor
Dr. Henning Bottcher
Gunter Holzemann
Joachim Leibrock
Kai Schiemann
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Patent GmbH
Original Assignee
Merck Patent GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent GmbH filed Critical Merck Patent GmbH
Publication of AU2002212226A1 publication Critical patent/AU2002212226A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
    • C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hospice & Palliative Care (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
AU2002212226A 2000-09-11 2001-09-10 Use of indole derivatives for treating illnesses of the central nervous system Abandoned AU2002212226A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE10045112 2000-09-11
DE10045112A DE10045112A1 (de) 2000-09-11 2000-09-11 Verwendung von Indolderivaten zur Behandlung von Erkrankungen des zentralen Nervensystems
PCT/EP2001/010443 WO2002020521A1 (de) 2000-09-11 2001-09-10 Verwendung von indolderivaten zur behandlung von erkrankungen des zentralen nervensystems

Publications (1)

Publication Number Publication Date
AU2002212226A1 true AU2002212226A1 (en) 2002-03-22

Family

ID=7655956

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2002212226A Abandoned AU2002212226A1 (en) 2000-09-11 2001-09-10 Use of indole derivatives for treating illnesses of the central nervous system

Country Status (3)

Country Link
AU (1) AU2002212226A1 (de)
DE (1) DE10045112A1 (de)
WO (1) WO2002020521A1 (de)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE0000540D0 (sv) 2000-02-18 2000-02-18 Astrazeneca Ab New compounds
DE10121217A1 (de) 2001-04-30 2002-10-31 Merck Patent Gmbh 6H-Oxazolo[4,5-e]indol-Derivate als nikotinische Acetylcholinrezeptor Liganden und/oder serotonerge Liganden
AU2003227522A1 (en) 2002-05-30 2003-12-19 Neurosearch A/S 3-substituted quinuclidines and their use
DE602004031124D1 (de) 2003-08-13 2011-03-03 Neurosearch As Neue chinuklidinderivative und deren pharmazeutische verwendung
SE0400970D0 (sv) * 2004-04-14 2004-04-14 Astrazeneca Ab Nicotinic acetylcholine receptor ligands
US8697722B2 (en) 2007-11-02 2014-04-15 Sri International Nicotinic acetylcholine receptor modulators
CA2787063C (en) 2010-01-11 2018-11-27 Astraea Therapeutics, Llc Nicotinic acetylcholine receptor modulators
WO2012131539A1 (en) 2011-03-31 2012-10-04 Pfizer Inc. Novel bicyclic pyridinones
WO2012172449A1 (en) 2011-06-13 2012-12-20 Pfizer Inc. Lactams as beta secretase inhibitors
EP2751116B1 (de) 2011-08-31 2016-10-12 Pfizer Inc Hexahydropyrano [3,4-d][1,3] thiazin-2-aminverbindungen
JP6110937B2 (ja) 2012-05-04 2017-04-05 ファイザー・インク ＡＰＰ、ＢＡＣＥ１、およびＢＡＣＥ２の阻害剤としての複素環式置換ヘキサヒドロピラノ［３，４−ｄ］［１，３］チアジン−２−アミン化合物
JP2015529239A (ja) 2012-09-20 2015-10-05 ファイザー・インク アルキル置換ヘキサヒドロピラノ［３，４−ｄ］［１，３］チアジン−２−アミン化合物
UA110688C2 (uk) 2012-09-21 2016-01-25 Пфайзер Інк. Біциклічні піридинони
EP2931731A1 (de) 2012-12-11 2015-10-21 Pfizer Inc. Hexahydropyrano-[3,4-d]-[1,3]-thiazin-2-aminverbindungen als bace1-inhibitoren
EP2935282A1 (de) 2012-12-19 2015-10-28 Pfizer Inc. Carbocyclisch und heterocyclisch substituierte hexahydropyrano[3,4-d]-[1,3]thiazin-2-amin-verbindungen
WO2014125394A1 (en) 2013-02-13 2014-08-21 Pfizer Inc. HETEROARYL-SUBSTITUTED HEXAHYDROPYRANO [3,4-d][1,3] THIAZIN-2-AMINE COMPOUNDS
US9233981B1 (en) 2013-02-15 2016-01-12 Pfizer Inc. Substituted phenyl hexahydropyrano[3,4-d][1,3]thiazin-2-amine compounds
AP2015008663A0 (en) 2013-02-19 2015-08-31 Pfizer Azabenzimidazole compounds as inhibitors of PDE4 isozymes for the treatment of cns and other disorders
ES2742078T3 (es) 2013-10-04 2020-02-13 Pfizer Piridonas bicíclicas novedosas como moduladores de gamma-secretasa
KR101886945B1 (ko) 2014-04-01 2018-08-08 화이자 인코포레이티드 감마-세크레타제 조절제로서의 크로멘 및 1,1a,2,7b-테트라히드로시클로프로파[c]크로멘 피리도피라진디온
MD20160105A2 (ro) 2014-04-10 2017-03-31 Pfizer Inc. 2-Amino-6-metil-4,4a,5,6-tetrahidropirano[3,4-d][1,3]tiazin-8a(8H)-il-1,3-tiazol-4-il amide
JP6713982B2 (ja) 2014-07-24 2020-06-24 ファイザー・インク ピラゾロピリミジン化合物
CU20170007A7 (es) 2014-08-06 2017-06-05 Pfizer Compuestos de imidazopiridazina
MX368391B (es) 2015-02-03 2019-09-30 Pfizer Ciclopropabenzofuranil-piridopirazindionas novedosas.
CN107787322B (zh) 2015-06-17 2023-07-07 辉瑞大药厂 三环化合物以及它们作为磷酸二酯酶抑制剂的用途
EP3353182A1 (de) 2015-09-24 2018-08-01 Pfizer Inc Tetrahydropyrano[3,4-d][1,3]oxazin-derivate und deren verwendung als bace-inhibitoren
WO2017051276A1 (en) 2015-09-24 2017-03-30 Pfizer Inc. N-[2-(2-amino-6,6-disubstituted-4, 4a, 5, 6-tetrahydropyrano [3,4-d][1,3] thiazin-8a (8h)-yl) -1, 3-thiazol-4-yl] amides
JP2018534251A (ja) 2015-09-24 2018-11-22 ファイザー・インク Ｂａｃｅ阻害剤として有用なｎ−［２−（３−アミノ−２，５−ジメチル−１，１−ジオキシド−５，６−ジヒドロ−２ｈ−１，２，４−チアジアジン−５−イル）−１，３−チアゾール−４−イル］アミド
EP3419979B1 (de) 2016-02-23 2020-01-29 Pfizer Inc 6,7-dihydro-5h-pyrazolo[5,1-b] [1,3]oxazin-2-carboxamidverbindungen
EP3872078A1 (de) 2016-07-01 2021-09-01 Pfizer Inc. 5,7-dihydro-pyrrolo-pyridin-derivate zur verwendung für die behandlung von depression, angst oder panikstörungen
JP7263266B2 (ja) 2017-06-22 2023-04-24 ファイザー・インク ジヒドロ－ピロロ－ピリジン誘導体
WO2019183636A1 (en) 2018-03-23 2019-09-26 Pfizer Inc. Piperazine azaspiro derivaves

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4009565A1 (de) * 1990-03-24 1991-09-26 Merck Patent Gmbh Indolderivate
DE4115215A1 (de) * 1991-05-10 1992-11-12 Merck Patent Gmbh Indolderivate

Also Published As

Publication number Publication date
WO2002020521A1 (de) 2002-03-14
DE10045112A1 (de) 2002-03-21

Similar Documents

Publication Publication Date Title
AU2002212226A1 (en) Use of indole derivatives for treating illnesses of the central nervous system
MXPA02008801A (es) Derivados de indol, proceso para la preparacion de los mismos y su uso.
AU6230098A (en) Isoquinolinone derivatives, process for preparing the same, and their use as phosphodiesterase inhibitors
AU4458700A (en) Uses of phenylglycine derivatives
IL155589A0 (en) Novel amidoalkyl-piperidine and amidoalkyl-piperazine derivatives useful for the treatment of nervous system disorders
AU5215700A (en) Substituted indolinone as tyrosine kinase inhibitors
IL160043A0 (en) Process for the preparation of indole derivatives
AU2001271706A1 (en) Use of substituted indole compounds for treating breast disorders
AU2001274049A1 (en) Process for the preparation of indole derivatives and intermediates of the process
AU4364400A (en) Azaindole derivatives for the treatment of depression
AU6062900A (en) Substituted indole compounds and their use for the treatment of cancer
AU7788500A (en) Use of substance p antagonists for influencing the circadian timing system
AU2002227895A1 (en) Sulphonamides for the treatment of central nervous system diseases
AU7388101A (en) Indole derivatives useful for the treatment of cns disorders
HK1059782A1 (en) Indole derivatives useful for the treatment of cnsdisorders
AU2709001A (en) Substituted tryptophan derivatives
GB2363605B (en) Process for the preparation of alpha-aminoketone derivatives
AU6476700A (en) Process for the preparation of indole derivatives or salts thereof
IL153254A0 (en) Indole derivatives useful for the treatment of cns disorders
AU2001241042A1 (en) Process for the preparation of hydrazine derivatives
AU2001264375A1 (en) Novel photosensitizers of 9-hydroxypheophorbide-a derivatives used for photocynamic therapy
AU2001261710A1 (en) Treatments and markers for cancers of the central nervous system
PL348758A1 (en) Use of n-substituted azabicycloalkane derivatives for treating diseases of the central nervous system
AU4475300A (en) Tetrahydroisoquinolinyl-indole derivatives for the treatment of depression
AU5197899A (en) Indole compounds, process for the preparation of the same and uses thereof